SPRO Spero Therapeutics Inc
Company Analysis
Latest News
Spero Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
For the second quarter of 2026, analysts expect Spero Therapeutics to report a consensus revenue of $0.28 million and a net loss of $0.17 per share, with the...
🟢 Spero Therapeutics is trading 5.2% up today tracking biotech sector strength
Spero Therapeutics is trading 5.2% up at $1.21 today, tracking broader strength across the biotechnology sector. • The stock is bouncing back after several...
🟢 Spero Therapeutics is trading 5.1% up today on thin after-hours liquidity and technical interest
Spero Therapeutics is trading 5.1% up at $1.23 following a modest rebound from recent weakness, likely driven by thin after-hours liquidity and technical...
🟢 Spero Therapeutics is trading 7.6% up today on technical rebound and thin after-hours liquidity
Spero Therapeutics is trading at $1.29 (+7.6%) in after-hours following a technical rebound from recent weakness. • No new company-specific headlines,...
🟢 Spero Therapeutics is trading 9.2% up today as it rebounds from recent weakness
Spero Therapeutics is trading 9.2% up at $1.30 in pre-market, rebounding from recent weakness in a move that appears to be a light-volume technical bounce. •...
🟢 Spero Therapeutics is trading 7.2% up today on a sharp intraday rebound despite no clear catalyst
Spero Therapeutics is trading at $1.26 (+7.20%) following a sharp intraday rebound despite a lack of company-specific news or direct corporate events. • The...
🟢 Spero Therapeutics is trading 5.2% up today following a technical rebound from recent sector weakness
Spero Therapeutics is trading 5.2% up at $1.22 as the stock stages a technical recovery following several sessions of sharp declines and broader biotech...
🔴 Spero Therapeutics is trading 5.1% down today as risk-off sentiment weighs on biotech
Spero Therapeutics is trading 5.1% down at $1.10 today, extending a series of sharp declines observed over the past week. • The downward move appears driven...
🔴 Spero Therapeutics is trading 6% down today, extending a week-long slide
Spero Therapeutics is trading at $1.09 (6% down) in pre-market, continuing a week-long slide after multiple prior sessions of sharp declines. • The move...
🔴 Spero Therapeutics is trading 10.2% down
Spero Therapeutics is trading at $1.14, down 10.2% from a comparison close of $1.27 during regular trading. This is a price-action follow-up, so a separate...
🔴 Spero Therapeutics shares extend losses, down 5.9% today, following investor reaction to $1.1B licensing deal and $105M financing
• Spero Therapeutics stock is trading at $1.60 (-5.88%), extending losses from a -22.02% drop on July 14, 2026. • The decline follows investor reaction to the...
Spero Therapeutics In-Licenses Immunology Drug, Secures $105M in Royalty Financing
Spero Therapeutics announced it has entered into an exclusive licensing agreement with Innovent Biologics for SP001, a Phase 2-ready anti-CD40L antibody....
🔴 Spero Therapeutics is trading 21.1% down today despite no clear company-specific catalyst
Spero Therapeutics is trading at $1.72 (-21.10%) following a sharp intraday decline that lacks a fresh company-specific announcement. • The move comes amid...
Spero Therapeutics Surges on $1.1B Licensing Deal, Extending Cash to 2029
Spero Therapeutics secured a $105 million non-dilutive royalty financing deal with Healthcare Royalty, a KKR affiliate. The financing relies on future...